Coagulation and Fibrinolysis in Thyroid Disease

Rennie, John; Bewsher, P. D.; Murchison, Lilian E.; Ogston, D.

doi:10.1159/000207759

Cited by 39 publications

(25 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decreased platelet adhesiveness, abnormal bleeding times, decreased levels of factors VIII, IX, XI and XII and a state with low vWF activity resembling acquired von Willebrand disease (vWD) and a bleeding tendency have been described especially in patients with OH (4 -9). On the other hand, some recent studies have suggested a hypercoagulable state, as shown by increases in platelet and factor VII activities and decreases in fibrinolytic activity, in severe hypothyroidism (10)(11)(12)(13)(14)(15). Changes in PAI-1 levels have also been shown in patients with hypothyroidism (12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism

2005

View full text Add to dashboard Cite

Objective: The aims of the study were to evaluate the disturbances in the coagulation system in patients with overt hypothyroidism (OH), to assess the effects of levothyroxine (LT4) on the coagulation parameters, and to determine whether subclinical hypothyroidism (SH) affects concentrations of coagulation markers and several biochemical parameters, thereby supporting early substitution. Design: The study included 15 patients with SH (TSH levels 5-10 mU/l), 15 patients with OH and 15 euthyroid controls. Methods: Blood urea nitrogen, creatinine, creatine phosphokinase, aspartate aminotransferase, lactate dehydrogenase, total-cholesterol, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol and triglyceride levels, and bleeding time, prothrombin time (PT), activated partial thromboplastin time (APTT), factor VIII activity, von Willebrand factor activity (vWF), platelet count and clotting time were evaluated just before and three months after the maintenance of euthyroidism with LT4 treatment. Results: Factor VIII and vWF activities were lower in patients with SH than in controls (P , 0.01). Increased bleeding time, PT, APTT and clotting time and decreased factor VIII activity and vWF activity were observed in patients with OH when compared with controls. Bleeding time, PT, APTT and clotting time decreased and factor VIII activity, vWF and platelet count increased after LT4 in patients with OH. Increases in factor VIII activity and vWF (P , 0.01) were detected also in the SH group with treatment. Conclusions: OH is associated with significant abnormalities in clotting parameters which are reversed by LT4. In contrast, SH is associated with minor changes in factor VIII activity and vWF which are reversible by LT4. Serum lipids and other measured parameters are not improved by LT4 in patients with TSH ,10 mU/l and these data fail to demonstrate a need to treat such patients. European Journal of Endocrinology 152 355-361

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism

2005

View full text Add to dashboard Cite

show abstract

“…However there was decreased capillary fragility in one of the studies done in hypothyroid states. But in majority of the studies, prolonged bleeding time was noted in hypothyroid patients [6,7,26,27] Decreased levels of clotting factors like factor VIII [27,28,29,30] ,IX,XI [6,29] ,XII [31][15-20] , factors VII [6] ,V,IX [6,29] & X found in hypothyroid condition was assumed to be due to generalised decrease in protein synthesis observed in hypothyroidism [32] . Prolonged clotting time was attributed to decreased levels of clotting factors.…”

Section: Analysis and Discussionmentioning

confidence: 99%

“…Increased fibrinolytic activity observed in hypothyroidism was normalised with thyroxine treatment. [36,31] There was simultaneous increase in plasminogen which was assumed to be because of increase in plasminogen activator [31,37,28] .…”

Section: Analysis and Discussionmentioning

confidence: 99%

Variation of Certain Haemostatic Parameters in Hypothyroidism

Vani¹

2017

JMSCR

View full text Add to dashboard Cite

show abstract

“…Its deficiency is often seen in severe liver diseases and acute disseminated intravascular coagulation, or as a result of thrombolytic therapy with plasminogen activators. 35 Elevated levels have been reported in conjunction with pregnancy, 36 hormonal contraceptives, 37 obesity, 38 anabolic steroids, 39 hypothyroidism, 40 and in liver or kidney transplant patients. 41 In this study, no significant change in plasminogen activity was noted for either GnRH-a treated or control groups.…”

Section: Discussionmentioning

confidence: 99%

Pelvic Adhesion and Gonadotropin-Releasing Hormone Analogue: Effects of Triptorelin Acetate Depot on Coagulation and Fibrinolytic Activities

et al. 2012

View full text Add to dashboard Cite

The study investigated the impact of gonadotropin-releasing hormone analogue (GnRH-a) on coagulation and fibrinolytic activities and its effectiveness in the prevention of pelvic adhesion after myomectomy. Thirty-two infertile women underwent myomectomy followed by adhesion evaluation surgery with a second-look laparoscopy. Before myomectomy, 15 women were treated with triptorelin acetate for 3 months and 17 received no treatment. Plasminogen activator inhibitor (PAI), thrombin activatable fibrinolysis inhibitor (TAFI), protein C (PC), plasminogen, α2-antiplasmin were determined by enzyme-linked immunosorbent assays and the activity of coagulation factors V and VIII by coagulometric methods. Patients treated with GnRH-a showed significant decrease in PAI, TAFI, factors V, and VIII (P < .05) and increased PC (P < .05), but no significant change in plasminogen and α2-antiplasmin levels compared with control group. The incidence, extent, and severity of adhesions were significantly lower in GnRH-a-treated patients compared with control group (P < .05), suggesting a possible critical role of the GnRH-a therapy in preventing postoperative adhesion development.

show abstract

Coagulation and Fibrinolysis in Thyroid Disease

Cited by 39 publications

References 19 publications

Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism

Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism

Variation of Certain Haemostatic Parameters in Hypothyroidism

Pelvic Adhesion and Gonadotropin-Releasing Hormone Analogue: Effects of Triptorelin Acetate Depot on Coagulation and Fibrinolytic Activities

Contact Info

Product

Resources

About